Imdusiran Drug Asset Due Diligence Report 2026

This Imdusiran Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Imdusiran can convert its siRNA profile and HBsAg biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Imdusiran (query alias: Imdusiran)
Modality / target	siRNA; HBsAg; HBsAg inhibitors, RNAi
Highest global status	Phase 2
Originator	Arbutus Biopharma Corp.
Active developers	Arbutus Biopharma Corp., Qilu Pharmaceutical Co., Ltd.

The MCP disease footprint includes Hepatitis B, Chronic, Hepatitis B. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06245291	Phase 2	Withdrawn	0	Primary endpoint not disclosed in English source
NCT06154278	Phase 2	Recruiting	10	Primary endpoint not disclosed in English source
ACTRN12622000317796	Phase 2	Completed	62	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection

Phase 2; n=43; evaluation: Not stated in English source. Reported fields: TEAE = 23 Pts ; TEAE = 11 Pts

Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: functional cure(HBsAg levels less than 1000 IU/mL) = 25 %

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Phase 2; n=62; evaluation: Positive. Reported fields: -; HBsAg loss = 3 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Imdusiran addresses Hepatitis B, Chronic, Hepatitis B. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—siRNA—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 4 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-06-25	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus	Phase 2	US$40.0M upfront; US$245.0M milestones; US$285.0M stated total
2021-07-06	Arbutus Biopharma to conduct phase IIa clinical trial of AB-729 in combination with Vaccitech's VTP-300 for CHBV infection.	Not disclosed	Financial terms not disclosed
2021-06-29	Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination treatments”. The milestone feed surfaced a patent-application signal described as “Hepatitis b combination therapies”. The milestone feed surfaced a patent-application signal described as “Oral delivery of oligonucleotides”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO